LONDON – Autolus Ltd. has launched with a £30 million (US$45.6 million) series A funding to develop chimeric antigen receptor (CAR) T-cell cancer therapies, which it claims will both overcome the serious side effects seen to date and move beyond B-cell targeting to address solid tumors.